These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35360663)

  • 61. Plasma and Lung Tissue Pharmacokinetics of Ceftaroline Fosamil in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass: an
    Edlinger-Stanger M; Al Jalali V; Andreas M; Jäger W; Böhmdorfer M; Zeitlinger M; Hutschala D
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0067921. PubMed ID: 34280013
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia.
    Jandourek A; Smith A; Llorens L; Thye DA; Eckburg PB; Friedland HD
    Hosp Pract (1995); 2014 Feb; 42(1):75-8. PubMed ID: 24566599
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.
    Esposito S; Carrothers TJ; Riccobene T; Stone GG; Kantecki M
    Paediatr Drugs; 2021 Nov; 23(6):549-563. PubMed ID: 34462863
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.
    Chan PLS; McFadyen L; Quaye A; Leister-Tebbe H; Hendrick VM; Hammond J; Raber S
    CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):551-563. PubMed ID: 33687148
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience.
    Lipsky BA; Cannon CM; Ramani A; Jandourek A; Calmaggi A; Friedland HD; Goldstein EJ
    Diabetes Metab Res Rev; 2015 May; 31(4):395-401. PubMed ID: 25417910
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ceftaroline fosamil: a novel broad-spectrum cephalosporin.
    Bazan JA; Martin SI
    Drugs Today (Barc); 2010 Oct; 46(10):743-55. PubMed ID: 21076711
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.
    Friedland HD; O'Neal T; Biek D; Eckburg PB; Rank DR; Llorens L; Smith A; Witherell GW; Laudano JB; Thye D
    Antimicrob Agents Chemother; 2012 May; 56(5):2231-6. PubMed ID: 22314524
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Novel Mechanism of Glass Delamination in Type 1A Borosilicate Vials Containing Frozen Protein Formulations.
    Jiang G; Goss M; Li G; Jing W; Shen H; Fujimori K; Le L; Wong L; Wen ZQ; Nashed-Samuel Y; Riker K; Germansderfer A; Tsang P; Ricci M
    PDA J Pharm Sci Technol; 2013; 67(4):323-35. PubMed ID: 23872443
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates.
    Housman ST; Keel RA; Crandon JL; Williams G; Nicolau DP
    Antimicrob Agents Chemother; 2012 May; 56(5):2576-80. PubMed ID: 22330908
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model.
    Bhalodi AA; Crandon JL; Williams G; Nicolau DP
    Int J Antimicrob Agents; 2014 Dec; 44(6):508-13. PubMed ID: 25278330
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.
    Drusano GL
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv33-9. PubMed ID: 21115453
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Methicillin-resistant Staphylococcus aureus epidural abscess treated with ceftaroline fosamil salvage therapy.
    Bucheit J; Collins R; Joshi P
    Am J Health Syst Pharm; 2014 Jan; 71(2):110-3. PubMed ID: 24375602
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE.
    Carreno JJ; Lodise TP
    Infect Dis Ther; 2014 Dec; 3(2):123-32. PubMed ID: 25193094
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.
    Van Wart SA; Forrest A; Khariton T; Rubino CM; Bhavnani SM; Reynolds DK; Riccobene T; Ambrose PG
    J Clin Pharmacol; 2013 Nov; 53(11):1155-67. PubMed ID: 23907740
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
    Critchley IA; Eckburg PB; Jandourek A; Biek D; Friedland HD; Thye DA
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii45-51. PubMed ID: 21482569
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators.
    Cristinacce A; Wright JG; Stone GG; Hammond J; McFadyen L; Raber S
    Infect Dis Ther; 2019 Jun; 8(2):185-198. PubMed ID: 30963520
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ceftaroline fosamil: a new broad-spectrum cephalosporin.
    Laudano JB
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii11-8. PubMed ID: 21482565
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.
    Van Wart SA; Ambrose PG; Rubino CM; Khariton T; Riccobene TA; Friedland HD; Critchley IA; Bhavnani SM
    Antimicrob Agents Chemother; 2014; 58(2):885-91. PubMed ID: 24277021
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Jorgenson MR; DePestel DD; Carver PL
    Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparative potencies of contemporary generic vancomycin lot: in vitro assay results from nine products and a reference reagent-grade sample.
    Jones RN; Watters AA; Flamm RK; Sader HS
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):237-8. PubMed ID: 23434498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.